focus -WSS

focus

author：leisure time 2025-09-03 05:40:39 - browse：7

Christoph Lengauer stands for a portrait. -- biotech coverage from STAT — Christoph Lengauer, co-founder and CSO of Curie.Bio Vanessa Leroy for STAT

Curie.Bio, the new biotech investment firm and incubator launched earlier this year by a group of industry veterans including Alexis Borisy and Zach Weinberg, has graduated its first startup.

The startup, Forward Therapeutics, is coming out of the incubator with three drug candidates for chronic inflammatory disorders. It also just closed its first major financing round: a $50 million Series A round led by BVF Partners, with participation from RA Capital Management and OrbiMed. That money should be enough for Forward to begin clinical trials — a rare feat in the biotech world, where companies often need to raise multiple private financing rounds in order to be ready for human tests.

“Usually, with Series A money, you get a development candidate, and use Series B to take molecules to the clinic,” Forward CEO Toufike Kanouni told STAT. But with the Curie team’s help, and the $8 million in seed financing it provided, Forward was able to move much faster.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Achieving telehealth equity for people with hearing loss

focus

WSS

Was Amgen transparent enough on FDA's concern on cancer drug?

3 questions for the future of Biden's cancer moonshot

Hospitals need to get ahead of regulations on climate change

Protect nursing home residents from future pandemics

FDA authorizes Novavax’s updated Covid

The world needs the new pandemic treaty

Wikipedia

focus

leisure time

Guidelines to prevent youth baseball injuries need more muscle

Chan Zuckerberg Biohub Chicago to focus on inflammation

New air purifier tech could be key to improving indoor air quality

Why age limits for politicians are a terrible idea

Alkermes shareholders re

Histogen: Failed biotech offers rare public look inside

Bright Health sells Medicare Advantage business to Molina

Why some fertility treatments produce more boy babies

How one medical school became remarkably diverse

3 questions for the future of Biden's cancer moonshot

leisure time

Protect nursing home residents from future pandemics

Unmasking the 'centricity' illusion in clinical trials

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

FDA panel signals lack of confidence in Amgen cancer drug data

Beyond aggravation: Constipation is an American epidemic

Pharma’s losing bet in New Jersey

focus

focus

focus

Wikipedia